Boehringer Ingelheim
Clinical trials sponsored by Boehringer Ingelheim, explained in plain language.
-
New drug combo shows promise in Tough-to-Treat cancer trial
Disease control Not yet recruitingThis study tests whether adding the experimental drug obrixtamig to standard chemotherapy helps people with advanced extrapulmonary neuroendocrine cancer live longer. About 390 adults will be randomly assigned to receive either the drug combo or chemo alone. The goal is to see if…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 17, 2026 15:08 UTC
-
New eye drug trial hopes to ease Diabetes-Related vision loss
Symptom relief Not yet recruitingThis early-stage study tests a new medicine, BI 3812465, in adults with diabetic macular edema (swelling in the center of the eye). The main goal is to see if different doses are safe and tolerable. Participants receive three injections into the eye over several months and are mo…
Phase: PHASE1, PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Symptom relief
Last updated May 17, 2026 15:12 UTC
-
New drug BI 3814916 put to the test in healthy volunteers
Knowledge-focused Not yet recruitingThis early-stage trial is testing a new drug called BI 3814916 in 136 healthy adults aged 18 to 65. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo, and no direct health benefit is expected.
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated May 17, 2026 15:13 UTC